アンジオテンシンI変換酵素阻害剤カプトプリルの脂質代謝に及ぼす効果:(I) 血清過酸化脂質低下作用について

概要

論文の詳細を見る
In order to evaluate the effect of the angiotensin I-converting enzyme inhibitor, captopril, on lipid metabolism, we measured serum lipoperoxides concentration (LPX) as well as plasma levels of renin activity (PRA), aldosterone (PAC) and bradykinin (PBK) before and after captopril administration in 15 hypertensive patients.<BR>Captopril significantly lowered the LPX (p<0.05 by repeated measures ANOVA) from the control value of 3.25±1.16 (mean±S.D.) to 2.92±0.94, 2.83±1.10, and 2.89±1.31 nmol/ml 30, 60, and 120 min after the administration, respectively.<BR>A significant reduction of blood pressure (p<0.0001) and PAC (p<0.01) was observed following captopril administration, while PBK increased significantly (p<0.001) from a baseline level of 10.85±4.07 to 13.95±5.29, 16.25±6.85, and 15.71±7.65 pg/ml 30, 60, and 120 min after captopril administration, respectively. There was no significant correlation between changes in serum LPX and in mean blood pressure, PRA and PAC, though a significant inverse relationship was found between changes in serum LPX and in PBK 120 min after the administration (r=-0.576, p<0.05, n=13). Although the mechanisms by which serum LPX is decreased by captopril are not clear, it is suggested from the results that captopril is a beneficial antihypertensive agent for preventing LPX-induced atherosclerosis in hypertensive patients.
一般社団法人日本内分泌学会の論文